KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
JERUSALEM and HOUSTON, Texas, Feb. 17, 2022 /PRNewswire/ — KAHR, a clinical stage oncology company developing novel dual-targeting fusion protein therapeutics, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer…
Comments Off on KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers